<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><atom:link href="https://pccarx.com/DesktopModules/LiveBlog/API/Syndication/GetRssFeeds?Tag=guidance-on-usp-sterile&amp;mid=8604&amp;PortalId=0&amp;tid=999&amp;ItemCount=20" rel="self" type="application/rss+xml" /><title>THE PCCA BLOG</title><description>Stay current on PCCA news and events, market trends, and all things compounding!</description><link>https://pccarx.com/Blog</link><item><title>USP 795: Revisions &amp; Impacts, Part 1</title><link>https://pccarx.com/Blog/usp-795-revisions-impacts-part-1?PostId=285</link><category>Pharmacy Legislation/Regulation</category><pubDate>Mon, 06 Feb 2023 14:33:14 GMT</pubDate><description>
	&lt;div class="PCCABlogPost"&gt;
&lt;p&gt;&lt;em&gt;by Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;On November 1, 2022, the United States Pharmacopeia (USP) published revisions to General Chapter 795, Pharmaceutical Compounding — Nonsterile Preparations (CNSPs), which becomes official and possibly enforceable in your state on November 1, 2023. The date also triggers potential enforcement of USP 800, which addresses CNSPs using hazardous drugs. &lt;br /&gt;
&lt;br /&gt;
For access to USP 795 revisions, USP offers two purchase options: the USP Compounding Compendium or the full USP-NF. Purchase of the USP Compounding Compendium grants access to more than 40 USP General Chapters, including 795, 797 and 800. Although purchase of the full USP-NF costs more, access includes USP chemical and product monographs, which are useful in determining how to use data from certificates of analysis. &lt;/p&gt;

&lt;h2&gt;USP 795 Revisions&lt;/h2&gt;

&lt;p&gt;USP offers a number of tools, including: &lt;/p&gt;

&lt;ul class="PCCABlogBullets"&gt;
	&lt;li&gt;
	&lt;p&gt;&lt;font color="#0000ff"&gt;&lt;u&gt;&lt;a href="https://go.usp.org/USP_GC_795_FAQs"&gt;USP 795 FAQs&lt;/a&gt;&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;&lt;font color="#0000ff"&gt;&lt;/font&gt;&lt;font color="#0000ff"&gt;&lt;u&gt;&lt;a href="https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/usp-nf-commentary/795-commentary-20221101.pdf?_ga=2.92664925.1596023849.1670518118-1266414170.1655818579"&gt;USP 795 Commentary&lt;/a&gt;&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;&lt;font color="#0000ff"&gt;&lt;u&gt;&lt;a href="https://uspevents.webex.com/recordingservice/sites/uspevents/recording/d83d929b419e103badb18e1b4c569c84/playback"&gt;USP 795 Open Forum Presentation&lt;/a&gt;&lt;/u&gt;&lt;/font&gt;&lt;font color="#777777"&gt; &lt;/font&gt;presented and recorded on November 8, 2022&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;&lt;font color="#0000ff"&gt;&lt;u&gt;&lt;a href="https://www.usp.org/sites/default/files/usp/document/events-and-training/2022-11-08-gc-795-open-forum-website-posting.pdf"&gt;USP 795 Open Forum Slides&lt;/a&gt;&lt;/u&gt;&lt;/font&gt;&lt;font color="#777777"&gt; &lt;/font&gt;presented on November 8, 2022&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;&lt;font color="#0000ff"&gt;&lt;u&gt;&lt;a href="https://go.usp.org/795_Flavoring.pdf"&gt;Adding Flavor to Conventionally Manufactured Nonsterile Product&lt;/a&gt;s&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
	&lt;/li&gt;
&lt;/ul&gt;

&lt;h2&gt;&lt;u&gt;&lt;/u&gt;Training&lt;/h2&gt;

&lt;p&gt;Revisions to USP 795 emphasize certain subtopics: specifically, a significant expansion and emphasis on training, including knowledge in and demonstration of core competencies. A trainee must show their ability to read and understand concepts and demonstrate their knowledge and ability to perform tasks, with documentation of all trainings and demonstrations. &lt;br /&gt;
&lt;br /&gt;
Core competencies include:&lt;/p&gt;

&lt;ul class="PCCABlogBullets"&gt;
	&lt;li&gt;Hand hygiene&lt;/li&gt;
	&lt;li&gt;Garbing&lt;/li&gt;
	&lt;li&gt;Cleaning and sanitizing&lt;/li&gt;
	&lt;li&gt;Handling and transporting components and CNSPs &lt;/li&gt;
	&lt;li&gt;Measuring and mixing&lt;/li&gt;
	&lt;li&gt;Proper use of equipment and devices selected to compound CNSPs&lt;/li&gt;
	&lt;li&gt;Documentation of the compounding process (described in Section 7 of the chapter, Master Formulation and Compounding Records)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;In addition, training must include:&lt;/p&gt;

&lt;ul class="PCCABlogBullets"&gt;
	&lt;li&gt;Ability to understand USP 795 requirements &lt;/li&gt;
	&lt;li&gt;Ability to understand and interpret safety data sheets (SDSs) and, if applicable, certificates of analysis (COAs)&lt;/li&gt;
	&lt;li&gt;Read and understand procedures related to their compounding duties&lt;/li&gt;
&lt;/ul&gt;

&lt;div&gt;Hand hygiene, garbing, cleaning and sanitizing are cited as significant core competencies for nonsterile compounding. While some may consider the purpose of garbing and personal protective equipment (PPE) is to protect compounders, the garbing process and PPE are significant tools that reduce skin cells shed and the microbes they can carry from potentially contaminating the compounded medication. In other words, properly donned PPE protects the compounder from chemicals and protects the compounded medication from potential contamination. &lt;/div&gt;

&lt;h2&gt;&lt;br /&gt;
Cleaning and Sanitizing&lt;/h2&gt;

&lt;div&gt;
&lt;p&gt;Table 1 in the USP 795 revisions define minimum schedules for cleaning and sanitizing nonsterile compounding area surfaces. USP has multiple chapters on microbial limits for nonsterile preparations, including USP 61 and USP 62. These chapters contain total microbial contamination limits and specific objectionable microorganisms prohibited in nonsterile compounds. The FDA also focuses on the quality of the compounding environment for CNSPs in their guidance, &lt;font color="#0000ff"&gt;&lt;u&gt;&lt;a href="https://www.fda.gov/media/124948/download" target="_blank"&gt;&lt;i&gt;Insanitary Conditions at Compounding Facilities&lt;/i&gt;&lt;/a&gt;&lt;/u&gt;&lt;/font&gt;.&lt;/p&gt;

&lt;h2&gt;&lt;br /&gt;
Beyond-Use Dates&lt;/h2&gt;
&lt;/div&gt;

&lt;div&gt;
&lt;p&gt;Beyond-use dates (BUDs) are always of significant interest to compounders because they affect patient care opportunities. When considering BUDs, it is common to look at the chemical and physical properties of an active pharmaceutical ingredient (API). The revisions to USP 795 also focus on the container closure system used for final formulations, including how the container closure may interact with CNSP API(s). Visually inspecting the integrity of the container closure after packaging and prior to release, as well as considering the possible container closure degradation over time, are all valuable. The integrity of the container closure is important because an improperly sealed, cracked or degraded container closure can potentially lead to microbial contamination or a loss of potency.&lt;/p&gt;

&lt;p&gt;PCCA offers resources to help pharmacies navigate the changing compounding standards and regulatory environment, including our blog on &lt;u&gt;&lt;a href="https://www.pccarx.com/Blog/2-fda-resources-that-can-help-protect-patients-minimize-risk-in-your-pharmacy" target="_blank"&gt;&lt;font color="#0000ff"&gt;FDA Insanitary Conditions&lt;/font&gt;&lt;/a&gt;&lt;/u&gt;&lt;u&gt;&lt;font color="#0088cc"&gt; &lt;/font&gt;&lt;/u&gt;and limited USP training courses at &lt;font color="#0000ff"&gt;&lt;u&gt;&lt;a href="https://www.pccarx.com/PCCANews/PCCAopensregistrationtoallcompoundersforpharmacycompoundingtrainingcoursesonqualitycomplianceandregulatoryrequirements" target="_blank"&gt;eLearning Compounding Training&lt;/a&gt;&lt;/u&gt;&lt;/font&gt;.&lt;i&gt;&lt;font color="#777777"&gt; &lt;/font&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p&gt;PCCA offers additional resources to our &lt;font color="#0000ff"&gt;&lt;u&gt;&lt;a href="https://www.pccarx.com/Membership" target="_blank"&gt;members&lt;/a&gt;&lt;/u&gt;&lt;/font&gt;, including all courses offered in our &lt;font color="#0000ff"&gt;&lt;u&gt;&lt;a href="https://pccarx.com/PCCAEducation/eLearning" target="_blank"&gt;eLearning Compounding Training&lt;/a&gt;&lt;/u&gt;&lt;/font&gt;, multiple &lt;font color="#0000ff"&gt;&lt;u&gt;&lt;a href="https://pccarx.com/PCCAEducation/Pharmacy" target="_blank"&gt;online webinars and training sessions&lt;/a&gt;&lt;/u&gt;&lt;/font&gt; and, for members with Clinical Services, &lt;font color="#0000ff"&gt;&lt;u&gt;&lt;a href="https://pccarx.com/PCCAEducation/SpeakersBureau" target="_blank"&gt;Speakers Bureau&lt;/a&gt;&lt;/u&gt;&lt;/font&gt; to guide, assist and educate compounding pharmacy staff. Members with Clinical Services may also contact our Clinical Services team for help with formulas and other compounding concerns.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;Part 2 of &lt;strong&gt;USP 795: Revisions &amp; Impacts &lt;/strong&gt;can be found &lt;strong&gt;&lt;a href="https://www.pccarx.com/Blog/usp-795-revisions-impacts-part-2" target="_blank"&gt;here.&lt;/a&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;The complete version of this article originally appeared in PCCA’s members-only magazine, the Apothagram.&lt;/em&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div id="addName" style="display: none;"&gt;membership&lt;/div&gt;
</description><guid isPermaLink="false">285</guid></item></channel></rss>